tiprankstipranks
Atossa Therapeutics (ATOS)
NASDAQ:ATOS

Atossa Therapeutics Stock Price & Analysis

1,793 Followers

ATOS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.81 - $3.53
Previous Close$0.82
Volume518.13K
Average Volume (3M)701.85K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$9.11M
Total Debt (Recent Filing)$1.22K
P/E Ratio-4.9
Beta-0.58
Next EarningsNov 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.17
Shares Outstanding126,624,110
R-Squared0.04
Standard Deviation0.45
10 Day Avg. Volume470,790
30 Day Avg. Volume701,852
P/B Ratio0.83
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-6.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside385.26% Upside
Rating ConsensusModerate Buy
Alpha0.02
Number of Analyst Covering2


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ATOS FAQ

What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $0.81 and its highest was $3.53 in the past 12 months.
    What is Atossa Therapeutics’s market cap?
    Currently, no data Available
    When is Atossa Therapeutics’s upcoming earnings report date?
    Atossa Therapeutics’s upcoming earnings report date is Nov 15, 2022 which is in 51 days.
      How were Atossa Therapeutics’s earnings last quarter?
      Atossa Therapeutics released its earnings results on Aug 15, 2022. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
        Is Atossa Therapeutics overvalued?
        According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Atossa Therapeutics pay dividends?
          Atossa Therapeutics does not currently pay dividends.
          What is Atossa Therapeutics’s EPS estimate?
          Atossa Therapeutics’s EPS estimate is -$0.06.
            How many shares outstanding does Atossa Therapeutics have?
            Atossa Therapeutics has 126,624,110 shares outstanding.
              What happened to Atossa Therapeutics’s price movement after its last earnings report?
              Atossa Therapeutics reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 5.556%.
                Which hedge fund is a major shareholder of Atossa Therapeutics?
                Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.

                  ---

                  Atossa Therapeutics Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  7
                  The Atossa Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Atossa Therapeutics

                  Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis